James I. Healy

James I. Healy, MD, Ph.D., has been a General Partner at Sofinnova Ventures, Inc., since 2000. Prior to this role, Dr. Healy held various positions at Bayer HealthCare Pharmaceuticals, Inc., Sanderling Ventures, and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors for Ascendis (ASND), Bolt (BOLT), Coherus (CHRS), Karuna (KRTX), Natera (NTRA), Nucana (NCNA), Y-mAbs (YMAB), and a board observer at Visen. Previously, Dr. Healy served as a board member for Amarin Corporation plc, Anthera Pharmaceuticals, Inc., Auris Medical Holding AG, Edge Therapeutics, Inc., Durata Therapeutics, Inc., Hyperion Therapeutics, Inc., InterMune, Inc., Interim Therapeutics plc, KaloBios Pharmaceuticals, Inc., CoTherix, Inc. and Movetis NV, in addition to a number of private companies. Dr. Healy holds a BA in Molecular Biology and a BA in Scandinavian Studies from the University of California, Berkeley, and an MD and a Ph.D. in Immunology from Stanford University School of Medicine, California.